Clinical Trial: Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma (NIMBUS)

Sponsor and Collaborators
Celgene Corporation

Contact
Contact: Associate Director, Clinical Trial Disclosure
1-888-260-1599
[email protected]


Continue Reading

Principal Investigator
Study Director: Mohamed Zaki, MD, PhD Celgene Corporation

ClinicalTrials.gov Identifier
NCT01311687